BioInvent International AB (OSTO:BINV) Dividends per Share : kr0.00 (TTM As of Sep. 2024)

View and export this data going back to 2001. Start your Free Trial

What is BioInvent International AB Dividends per Share?

BioInvent International AB's dividends per share for the three months ended in Sep. 2024 was kr0.00. Its dividends per share for the trailing twelve months (TTM) ended in Sep. 2024 was kr0.00. Its Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00. As of today, BioInvent International AB's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

BioInvent International AB Dividends per Share Historical Data

The historical data trend for BioInvent International AB's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB Dividends per Share Chart

BioInvent International AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividends per Share

Get a 7-Day Free Trial

BioInvent International AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BioInvent International AB's Dividends per Share

For the Biotechnology subindustry, BioInvent International AB's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioInvent International AB's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's Dividend Yield % falls into.

BioInvent International AB Dividends per Share Calculation

Dividends paid to per common share.

BioInvent International AB (OSTO:BINV) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

BioInvent International AB's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2024 )	/	EPS without NRI (Q: Sep. 2024 )
	=	0	/	-1.6
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

BioInvent International AB Dividends per Share Related Terms

Thank you for viewing the detailed overview of BioInvent International AB's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

BioInvent International AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (OSTO:BINV) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

0H22:UK BIX:Germany

Address

Ideongatan 1, Lund, SWE, SE-223 70

Website

https://www.bioinvent.com

BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB Headlines

No Headlines